Arch Pharmalabs Ltd, a leading supplier of API (Active Pharmaceuticals Ingredients) and Intermediates, has received a new verification mark for a drug substance from US Pharmacopoeia (USP) under the Pharmaceutical Ingredient Verification Programme (PIVP) at their Gurgaon manufacturing facility.
USP created the PIVP as an independent, ethical, and credible third party verification for quality compliance thus adding one more element of safety and comfort for manufacturers and their customers. This was done to address increasing concerns throughout the pharmaceutical industry about the quality and consistency of pharmaceutical ingredients.
The programme enables manufacturers to showcase their quality and integrity of their products with a recognizable 'USP Verified' mark. Arch Pharmalabs has received this verification for Clopidogrel Bisulfate (Form1). This mark can be used by Arch Pharmalabs on the certificate of analysis and other bulk-label containers of this product.
Commenting on this development, Ajit Kamath, CMD, Arch Pharmalabs Ltd said, "This USP verification mark signifies our commitment to the very stringent processes and quality standards we follow at Arch Pharmalabs. We have undergone rigorous and independent conformity assessments to receive this certification. We further, look forward to working closely, with USP PIVP and exposing our other products to this respectful certification."
The US Pharmacopoeia (USP) verification assures consistency of quality in process (good manufacturing practice) and product.
Mumbai-based, Arch Pharmalabs can be known as a 'Turn-around Strategist'; acquiring companies and turning them around to fully integrate them in Arch Pharmalabs' business as 'profit making centers'.